KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Shares Outstanding (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Shares Outstanding for 14 consecutive years, with $90.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 3.97% year-over-year to $90.9 million, compared with a TTM value of $90.9 million through Dec 2025, up 3.97%, and an annual FY2025 reading of $90.9 million, up 3.97% over the prior year.
  • Shares Outstanding was $90.9 million for Q4 2025 at Travere Therapeutics, up from $89.5 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $90.9 million in Q4 2025 and bottomed at $60.4 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $73.8 million, with a median of $75.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding surged 40.05% in 2021, then grew 1.98% in 2024.
  • Year by year, Shares Outstanding stood at $62.5 million in 2021, then increased by 2.88% to $64.3 million in 2022, then increased by 17.23% to $75.4 million in 2023, then grew by 16.04% to $87.5 million in 2024, then increased by 3.97% to $90.9 million in 2025.
  • Business Quant data shows Shares Outstanding for TVTX at $90.9 million in Q4 2025, $89.5 million in Q3 2025, and $89.1 million in Q2 2025.